114 related articles for article (PubMed ID: 26657199)
21. Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
Macarulla T; Cervantes A; Tabernero J; Roselló S; Van Cutsem E; Tejpar S; Prenen H; Martinelli E; Troiani T; Laffranchi B; Jego V; von Richter O; Ciardiello F
Br J Cancer; 2015 Jun; 112(12):1874-81. PubMed ID: 25989270
[TBL] [Abstract][Full Text] [Related]
22. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.
Parvinian A; Casadaban LC; Hauck ZZ; van Breemen RB; Gaba RC
Diagn Interv Radiol; 2015; 21(3):235-40. PubMed ID: 25835078
[TBL] [Abstract][Full Text] [Related]
24. Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here?
Efficace F; Novik A; Vignetti M; Mandelli F; Cleeland CS
Haematologica; 2007 Dec; 92(12):1596-8. PubMed ID: 18055981
[No Abstract] [Full Text] [Related]
25. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
26. The challenges and perspectives in treating adolescent and young adult patients with hematological malignancies.
Raanani P; Tallman MS
Acta Haematol; 2014; 132(3-4):263. PubMed ID: 25228550
[No Abstract] [Full Text] [Related]
27. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Craver C; Gayle J; Balu S; Buchner D
J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
[TBL] [Abstract][Full Text] [Related]
28. Case of sorafenib-induced thyroid storm.
Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
[No Abstract] [Full Text] [Related]
29. [Improvement of Meals for Patients Undergoing Chemotherapy].
Takeishi A; Satoh M; Sato S; Takanashi A; Henmi N; Miura K
Gan To Kagaku Ryoho; 2018 May; 45(5):883-885. PubMed ID: 30026458
[No Abstract] [Full Text] [Related]
30. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Rizzieri DA; Feldman E; Dipersio JF; Gabrail N; Stock W; Strair R; Rivera VM; Albitar M; Bedrosian CL; Giles FJ
Clin Cancer Res; 2008 May; 14(9):2756-62. PubMed ID: 18451242
[TBL] [Abstract][Full Text] [Related]
31. [Chemotherapy].
Ueda T
Nihon Rinsho; 2012 Apr; 70 Suppl 2():202-6. PubMed ID: 23133953
[No Abstract] [Full Text] [Related]
32. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Park H; Han SH; Kang H; Park K
Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
[No Abstract] [Full Text] [Related]
33. The suggestion of a risk stratification system for febrile neutropenia in patients with hematologic disease.
Park Y; Kim DS; Park SJ; Seo HY; Lee SR; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Leuk Res; 2010 Mar; 34(3):294-300. PubMed ID: 19762083
[TBL] [Abstract][Full Text] [Related]
34. Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma.
Kim EH; Kim BK; Kim DY; Kim SU
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):514-5. PubMed ID: 23466449
[No Abstract] [Full Text] [Related]
35. Bendamustine: a novel cytotoxic agent for hematologic malignancies.
Blumel S; Goodrich A; Martin C; Dang NH
Clin J Oncol Nurs; 2008 Oct; 12(5):799-806. PubMed ID: 18842536
[TBL] [Abstract][Full Text] [Related]
36. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
37. Farnesyl transferase inhibition in hematologic malignancies.
Karp JE
J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S37-40. PubMed ID: 16280111
[No Abstract] [Full Text] [Related]
38. Effects of chemotherapy on plasma lipids and lipoproteins in Nigerian patients with haematological malignancy.
Idogun SE; Omoti CE
Niger Postgrad Med J; 2011 Mar; 18(1):16-9. PubMed ID: 21445108
[TBL] [Abstract][Full Text] [Related]
39. An open-label phase I dose-finding study of APR-246 in hematological malignancies.
Deneberg S; Cherif H; Lazarevic V; Andersson PO; von Euler M; Juliusson G; Lehmann S
Blood Cancer J; 2016 Jul; 6(7):e447. PubMed ID: 27421096
[No Abstract] [Full Text] [Related]
40. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
Zhou Q; Zhou CC; Chen GY; Cheng Y; Huang C; Zhang L; Xu CR; Li AW; Yan HH; Su J; Zhang XC; Yang JJ; Wu YL
Lung Cancer; 2014 Mar; 83(3):369-73. PubMed ID: 24440279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
